Rosacea. Rosacea
Conditions
Interventions
Intervention 1: Each patient randomly applied the permethrin 5% gel on the clean skin of one side of the face twice daily for 12 weeks. Intervention 2: Each patient randomly applied the placebo gel on
Treatment - Drugs
Placebo
Each patient randomly applied the permethrin 5% gel on the clean skin of one side of the face twice daily for 12 weeks.
Each patient randomly applied the placebo gel on the clean skin of one side of the face twice daily for 12 weeks.
Sponsors
Deputy of Research, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Papulopustular rosacea patients; At least 5 mites per square centimeter in the facial biopsy samples of both left and right sides; At least 18 years old, regardless of gender; Exclusion criteria: Rosacea patients with less than 5 mites per square centimeter in the facial biopsy samples of one or both left and right sides; Patients with different types of skin cancers; Patients with severe skin infections; Patients with severe burnings; Sensitivity to permethrin; Pregnant women; Breastfeeding women
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Density of Demodex mites per square centimeter of the facial surface on the left and right sides. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation for both sides of the face. Method of measurement: Demodex densities per square centimeter of the facial surface on the left and right sides were determined by standard skin surface biopsy at the baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical presentations of rosacea patients including: transient erythema, nontransient erythema, papules and pustules, telangiectasia, burning or stinging, plaque, dry appearance, edema, ocular manifestations, and phymatous changes. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation for both sides of the face. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard at the baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Kosar Raoufinejad
Department of Clinical Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Ir
Outcome results
None listed